Home > Pressrelease > Plasma Derived Therapy Market size to exceed $32bn by 2030

Plasma Derived Therapy Market size to exceed $32bn by 2030

  • Published Date: May 27, 2022

Plasma Derived Therapy Market size is set to surpass USD 32 billion by 2030, according to a new research report by Global Market Insights Inc.

Rising adoption of immunoglobulin across nation is expected to boost the market forecasts. Plasma-derived immunoglobulin is widely used for a range of inflammatory and autoimmune diseases. Surge in recognition and treatment of immune deficiencies has increased demand for immunoglobulins. Moreover, the number of clinical indications for plasma derived products has been growing in recent years. Immunoglobulin has become a key treatment option in several clinical indications including acute inflammatory and autoimmune conditions. Demand for such therapies is rising because of off-label use in various applications, particularly for the treatment of immunological deficiencies and neurological disorders.

The rising development of new plasma collection centers by the major plasma derived therapy industry players is anticipated to drive the market demand. For instance, in March 2022, ADMA Biologics announced U.S. FDA approval for its 5th ADMA BioCenters plasma collection facility at Georgia. Therefore, successful expansion of such plasma collection centers will spur the industry statistics. Furthermore, increasing awareness regarding blood donation and blood related disorders is further projected to accelerate industry progression.

Increasing prevalence of hemophilia among population will influence the industry expansion

Coagulation factors segment was accounted for 15% market share in 2021 and is set to register a significant CAGR through 2030. This is attributable to growing prevalence of hemophilia disorders coupled with significant investment towards development of effective treatment. According to the Centers for Disease Control and Prevention (CDC) in the U.S. hemophilia affects approximately 1 in 5,617 male births. Therefore, increasing number of patients suffering from hemophilia will propel the market trends.

Browse key industry insights spread across 108 pages with 123 market data tables & 11 figures & charts from the report, “Plasma Derived Therapy Market Analysis By Product (Coagulation Factors, Immunoglobulins, Albumin), Application (Primary Immunodeficiency Diseases, Hemophilia, Idiopathic Thrombocytopenic Purpura (ITP)), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030 in detail along with the table of contents:


Increasing preference for plasma derived therapies for treatment of rare diseases will augment the market outlook 

Plasma derived therapy market from primary immunodeficiency diseases segment held over USD 4.2 billion in 2021. This is owing to increasing awareness regarding plasma derived therapy for the treatment of primary immunodeficiency disease. It is a genetic disorder in the immune system that represents a missing part or abnormal function Moreover, increasing research and development activities for the development of advanced plasma derived therapy will further contribute to the segment revenue.

Growing elderly population susceptible to suffer from rare diseases in Europe will augment the industry scenario

Europe plasma derived therapy market is estimated to progress at 7.2% CAGR during the analysis period. The is due to the rising geriatric population base that is more susceptible to several immunological and neurological disorders and is said to gradually increase the demand for plasma derived therapy. Additionally, the companies operating in the region are increasingly focusing on the introduction of innovative therapy for diseases management. Thus, increasing investment in plasma fractionation coupled with availability of well-equipped facilities will stimulate the regional business landscape.

Strategic collaborations by the leading industry players will strengthen their business reach

Some of the major players operating in the plasma derived therapy industry are CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kedrion, Kamada Pharmaceuticals, SK Plasma, Pfizer. These companies are undertaking several business growth strategies such as acquisitions and collaborations to expand their business presence.

For instance, in July 2021, Octapharma AG received FDA approval for its Octagram 10%, intravenous immunoglobulin (IVIg). The product is used for treatment of rare immune-mediated inflammatory disease “adult dermatomyositis”. Therefore, such products approvals will help company to strengthen its product portfolio and generate more revenues.

Authors: Sumant Ugalmugale, Rupali Swain